Latanoprostene bunod

Generic Medicine Info
Indications and Dosage
Ocular hypertension, Open-angle glaucoma
Adult: As 0.024% solution: Instil 1 drop into the conjunctival sac of the affected eye(s) once daily in the evening. Max: 1 drop once daily.
Child: >16 years Same as adult dose.
Active intraocular inflammation.
Special Precautions
Patient with history of intraocular inflammation (e.g. uveitis, iritis), aphakia, pseudophakia with torn posterior lens capsule, known risk factors for macular oedema. Pregnancy and lactation.
Adverse Reactions
Significant: Change or increase in the brown pigmentation of the iris and eyelid skin; change or increase in the pigmentation, length, number or thickness of eyelashes (reversible); intraocular inflammation; macular oedema, including cystoid macular oedema; bacterial keratitis (when the multiple-dose container used is inadvertently contaminated).
Eye disorders: Conjunctival hyperaemia, eye irritation or pain, instillation site pain, conjunctival oedema, blurred vision, punctate keratitis, foreign body sensation.
Patient Counseling Information
Remove contact lenses prior to administration and reinsert after 15 minutes.
Monitoring Parameters
Monitor intraocular pressure. Regularly assess patients who develop increased iris pigmentation.
Mechanism of Action: Latanoprostene bunod is a nitric oxide-donating synthetic analogue of naturally occurring prostaglandin F. It is a prodrug and thought to increase the outflow of aqueous humour through both the trabecular meshwork (conventional route mediated by nitric oxide) and uveoscleral pathway (nonconventional route mediated by latanoprost acid), thus lowering the intraocular pressure.
Onset: Reduction of intraocular pressure: Approx 1-3 hours; 11-13 hours (max effect).
Absorption: Time to peak plasma concentration: Approx 5 minutes (latanoprost acid).
Metabolism: Rapidly metabolised in the eye to latanoprost acid (active metabolite; F prostaglandin analogue) and butanediol mononitrate. Latanoprost acid is further metabolised mainly in the liver after reaching the systemic circulation via fatty acid β-oxidation to 1,2-dinor and 1,2,3,4-tetranor metabolites. Butanediol mononitrate is metabolised to 1,4-butanediol and nitric oxide; 1,4-butanediol undergoes further oxidation to form succinic acid and enters tricarboxylic acid (TCA) cycle.
Chemical Structure

Chemical Structure Image
Latanoprostene bunod

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 11156438, Latanoprostene BUNOD. Accessed Feb. 22, 2021.

Store unopened bottle between 2-8°C. Once opened, may store between 2-25°C for up to 8 weeks. Do not freeze. Protect from light.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01EE06 - latanoprostene bunod ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Anon. Latanoprostene Bunod. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 04/02/2021.

Anon. Latanoprostene Bunod. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/02/2021.

Buckingham R (ed). Latanoprostene Bunod. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/02/2021.

Latanoprostene Bunod. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. Accessed 08/02/2021.

Vyzulta Ophthalmic Solution 0.024% (Bausch & Lomb [Hong Kong] Ltd). MIMS Hong Kong. Accessed 04/02/2021.

Vyzulta Ophthalmic Solution 0.024% (Bausch & Lomb Incorporated). U.S. FDA. Accessed 08/02/2021.

Vyzulta Solution/Drops (Bausch & Lomb Incorporated). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/02/2021.

Disclaimer: This information is independently developed by MIMS based on Latanoprostene bunod from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in